Trials / Completed
CompletedNCT02885974
Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer
Pilot Study of Celecoxib Combined With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Localized, Muscle-Invasive Bladder Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Baylor College of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare patient tumor tissue before and after treatment with chemotherapy plus celecoxib. Investigators will look at gene expression, to see what effect celecoxib may have on tumor cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celecoxib | Celecoxib (100 mg daily) |
| DRUG | Gemcitabine | 1,000 mg/m2 (IV), on Days 1 and 8 of each 21-day cycle. Up to 4 cycles. |
| DRUG | Cisplatin | 70 mg/m2 (IV), on Day 1 of each 21-day cycle. Up to 4 cycles. |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2024-03-01
- Completion
- 2025-03-01
- First posted
- 2016-09-01
- Last updated
- 2025-07-28
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02885974. Inclusion in this directory is not an endorsement.